New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?
- PMID: 32042641
- PMCID: PMC6989844
- DOI: 10.21037/tau.2019.12.34
New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Comment on
-
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Lancet Oncol. 2019. PMID: 31375469 Free PMC article. Clinical Trial.
Similar articles
-
Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy.Br J Urol. 1991 Jun;67(6):626-31. doi: 10.1111/j.1464-410x.1991.tb15228.x. Br J Urol. 1991. PMID: 1712655
-
Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.Urology. 2007 Nov;70(5):950-5. doi: 10.1016/j.urology.2007.06.1119. Urology. 2007. PMID: 18068453
-
Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10. Eur Urol. 2018. PMID: 29233664 Free PMC article.
-
Therapeutic radiation in patients with a rising post-prostatectomy PSA level.Oncology (Williston Park). 1998 Jan;12(1):33-9; discussion 39, 43-4, 47. Oncology (Williston Park). 1998. PMID: 9474586 Review.
-
Variables in predicting survival based on treating "PSA-only" relapse.Urol Oncol. 2003 Jul-Aug;21(4):292-304. doi: 10.1016/s1078-1439(03)00103-0. Urol Oncol. 2003. PMID: 12954500 Review.
Cited by
-
Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.Radiat Oncol. 2021 Jun 23;16(1):114. doi: 10.1186/s13014-021-01839-w. Radiat Oncol. 2021. PMID: 34162398 Free PMC article.
-
Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.Radiat Oncol. 2021 May 12;16(1):88. doi: 10.1186/s13014-021-01808-3. Radiat Oncol. 2021. PMID: 33980277 Free PMC article. Clinical Trial.
-
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting.Radiol Med. 2022 Feb;127(2):206-213. doi: 10.1007/s11547-021-01435-8. Epub 2021 Nov 30. Radiol Med. 2022. PMID: 34850352
-
Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.Radiol Med. 2021 Jul;126(7):989-997. doi: 10.1007/s11547-021-01352-w. Epub 2021 Apr 9. Radiol Med. 2021. PMID: 33835309
-
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance.Med Oncol. 2021 May 18;38(6):72. doi: 10.1007/s12032-021-01518-6. Med Oncol. 2021. PMID: 34008151 Free PMC article.
References
-
- National Comprehensive Cancer Network. Guidelines for treatment of cancer by site: prostate cancer. Version 4.2019. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous